SCHEMBL6717435

SCHEMBL6717435

Cc1ccccc1NC(=O)C(C)N(S)C(=O)Nc1ccccc1[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
MAPT P10636 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
DDX3X O00571 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723934 0.89 KMT2A (0.45) KMT2AMEN1ALDH1A1LMNAGRIN2D
SCHEMBL6713943 0.89 KMT2A (0.45) KMT2AMEN1ALDH1A1LMNAGRIN2D
SCHEMBL6716855 0.89 KMT2A (0.45) KMT2AMEN1ALDH1A1LMNAGRIN2D
SCHEMBL6716840 0.86 KMT2A (0.49) KMT2AMEN1ALDH1A1LMNAGRIN2D
SCHEMBL6713814 0.86 KMT2A (0.49) KMT2AMEN1ALDH1A1LMNAGRIN2D
SCHEMBL6716242 0.86 KMT2A (0.44) KMT2AMEN1ALDH1A1LMNAGRIN2D
SCHEMBL6723400 0.83 POLB (0.46) KMT2AMEN1ALDH1A1LMNAGRIN2D
SCHEMBL6723576 0.81 KMT2A (0.51) KMT2AMEN1ALDH1A1LMNAGRIN2D
SCHEMBL6723190 0.81 KMT2A (0.51) KMT2AMEN1ALDH1A1LMNAGRIN2D
SCHEMBL6717476 0.80 MAPT (0.41) KMT2AMEN1ALDH1A1LMNAGRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 KMT2A 2020/4885MEN1 2933/4885ALDH1A1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.